Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 3.6% ...

Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...

Regeneron’s second quarter was marked by robust growth in key products, which the company attributed to the strong commercial ...

Truist on Monday lowered its price target on Regeneron (REGN) to $812 from $940, citing concerns with the company’s Eylea ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds ...

Regeneron Court Permits Government to Pursue False Certification Theory - On August 4, the district court in the closely ...

The company is streamlining its global workforce as part of a multi-year cost-cutting strategy, while raising its 2025 ...

Q2 2025 Earnings Call Transcript August 5, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $6.02, expectations ...

Second-Quarter 2025 and Recent Selected Highlights: <li /> Total revenues of $63.7 million, a 30% increase over $48.

With autonomy from its former parent, we think Sandoz can freely allocate resources to fit its best needs and grow the business. Sandoz is one of the largest biosimilars players in the world, and we ...

Half Year Results/Half Year ReportFormycon confirms full-year guidance following business development in line with plan – working capital raised 13.08.2025 / 06:30 CET/CESTThe issuer is solely ...

The competitive landscape of the ARMD market in 2025 is dominated by a few key players and a leading product. Eylea, a therapy for age-related molecular degeneration, is projected to command a ...